Needham Reiterates Buy on Cellebrite DI, Maintains $24 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $24 price target.
Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $24 price target.